Pelacarsen: Mechanism of action and Lp(a)-lowering effect

医学 机制(生物学) 动作(物理) 作用机理 药理学 遗传学 认识论 量子力学 生物 物理 哲学 体外
作者
Harpreet Singh Bhatia,Archna Bajaj,Sascha N. Goonewardena,Patrick M. Moriarty
出处
期刊:Journal of Clinical Lipidology [Elsevier BV]
卷期号:19 (5): 1208-1222 被引量:24
标识
DOI:10.1016/j.jacl.2025.06.004
摘要

BACKGROUND: Lipoprotein(a) (Lp[a]) is an apolipoprotein B100 (apoB)-containing lipoprotein with a single apolipoprotein(a) (apo[a]) covalently bound to apoB via a disulfide bond and oxidized phospholipids linked to apoB and apo(a), which is associated with proinflammatory, prothrombotic, and proatherogenic mechanisms. Elevated Lp(a) (≥125 nmol/L [≥50 mg/dL]) is an independent, causal, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD), affecting >1.4 billion individuals worldwide. SOURCES OF MATERIAL: There are no pharmacological Lp(a)-lowering therapies approved in the United States; however, lipoprotein apheresis may be considered under certain circumstances. Germany is the only country where apheresis is approved for patients with elevated Lp(a) and progressing ASCVD. ABSTRACT OF FINDINGS: Existing lipid-lowering therapies including proprotein convertase subtilisin/kexin type 9 inhibitors have shown modest effects on Lp(a) levels but fallen short of clinically meaningful reductions of >50 to 100 mg/dL. Several Lp(a)-lowering, RNA-targeted agents are in development, including antisense oligonucleotides (ASOs) and small interfering RNAs. Pelacarsen is a second-generation ASO that targets the production of apo(a) and includes chemical modifications such as triantennary N-acetylgalactosamine that improve biostability, decrease off-target toxicity compared with unmodified ASOs, and allow rapid, specific uptake by hepatocytes, the site of apo(a) synthesis. A phase 2b study of pelacarsen showed ≥80% reduction in Lp(a) concentration with a favorable safety profile in patients with established ASCVD. CONCLUSION: The ongoing phase 3 Lp(a)HORIZON study is evaluating whether the Lp(a)-lowering effects of pelacarsen translate into reductions in the incidence of major cardiovascular events, also in patients with established ASCVD. Herein, we review the mechanism of action of pelacarsen and evidence for its Lp(a)-lowering effects.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
轻烟藏雨巷完成签到 ,获得积分10
刚刚
太阳完成签到,获得积分10
刚刚
坚定的又莲完成签到 ,获得积分10
1秒前
小郭小郭福气多多完成签到,获得积分10
1秒前
小黑莓完成签到,获得积分10
1秒前
orixero的应助被荒谬采纳,获得10
1秒前
FashionBoy的应助被懒惰依秋采纳,获得10
1秒前
111完成签到,获得积分10
1秒前
桥边黄药师完成签到,获得积分10
1秒前
阳的鱼仔发布了新的文献求助10
2秒前
小马甲的应助被王梦姣采纳,获得20
2秒前
平城时代完成签到,获得积分10
2秒前
丘溪4761完成签到,获得积分10
2秒前
123完成签到,获得积分10
2秒前
高小高完成签到,获得积分10
2秒前
2秒前
3秒前
zyy完成签到,获得积分10
3秒前
南风完成签到,获得积分10
3秒前
3秒前
小c完成签到,获得积分10
3秒前
feifei完成签到,获得积分10
4秒前
4秒前
浮生完成签到,获得积分10
4秒前
weigaozhao完成签到,获得积分10
4秒前
lili完成签到,获得积分10
4秒前
每每完成签到,获得积分10
4秒前
黄金弗利萨完成签到,获得积分10
4秒前
4秒前
Lumos完成签到 ,获得积分10
5秒前
科研通AI6.2的应助被猪猪hero采纳,获得10
5秒前
滴滴滴完成签到,获得积分10
5秒前
SanXing三醒完成签到,获得积分10
5秒前
yunfulu29完成签到,获得积分10
5秒前
yzh发布了新的文献求助10
6秒前
Bainville完成签到,获得积分10
6秒前
zm发布了新的文献求助10
6秒前
邵简完成签到,获得积分10
7秒前
虾球完成签到,获得积分10
7秒前
广州队完成签到,获得积分0
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152226
求助须知:如何正确求助?哪些是违规求助? 9549007
关于积分的说明 21689901
捐赠科研通 7740494
什么是DOI,文献DOI怎么找? 3425145
关于科研通互助平台的介绍 2550358
邀请新用户注册赠送积分活动 2468652